Login Register Cart 0
Generic placeholder image

Current Bioactive Compounds

Editor-in-Chief

ISSN (Print): 1573-4072
ISSN (Online): 1875-6646

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Pharmaceutical Potential of Constituents from Azadirachta indica and their Specific Role as Anti-cancer Agents

Author(s): Ishtiaq Jeelani*, Mrinalini Bhosale, Tanzeela Qadir, Praveen Kumar Sharma, Allah Nawaz, Aamir Sharif, Andleeb Amin, Alisha Sheikh, Saeed Ahmad, Vinita Kukreja, Snehal Kulkarni and Subhash Padhye

Volume 19, Issue 3, 2023

Published on: 12 October, 2022

Article ID: e180822207631 Pages: 10

DOI: 10.2174/1573407218666220818110059

Price: $65

Abstract

Neem (Azadirachta indica), a Meliaceae family member, is a rapidly growing tropical evergreen tree with a thick, branching trunk. It has been used for hundreds of years in traditional Indian medicine as a home cure against numerous human illnesses in the Indian and African continents. Different components of the plant, including the flowers, leaves, seeds, and bark, have been used to treat both acute and chronic human illnesses, as well as an insecticide, antibiotic, larvicidal, antimalarial, antibacterial, antiviral, and spermicidal. The plant's anticancer qualities have been extensively researched in terms of its preventative, protective, tumor-suppressive, immunomodulatory, and apoptotic actions against different cancers and their molecular processes. Triple-negative breast cancer (TNBC), which lacks the expression of progesterone and estrogen receptors, has a dismal prognosis and no viable therapeutic options. Gedunin compound isolated from Azadirachta indica's seed oil shows potential anticancer effect against triple-negative breast cancer (TNBC) cancer cells, which acts as heat shock protein 90 (Hsp90) inhibitor.

Keywords: : Neem, India, tree, Azadirachta indica, TNBC, anticancer.

Graphical Abstract

[1]
Kumar, V.S.; Navaratnam, V. Neem (Azadirachta indica): Prehistory to contemporary medicinal uses to humankind. Asian Pac. J. Trop. Biomed., 2013, 3(7), 505-514.
[http://dx.doi.org/10.1016/S2221-1691(13)60105-7] [PMID: 23835719]
[2]
Subapriya, R.; Nagini, S. Medicinal properties of neem leaves: A review. Curr. Med. Chem. Anticancer Agents, 2005, 5(2), 149-6.
[http://dx.doi.org/10.2174/1568011053174828] [PMID: 15777222]
[3]
Pankaj, S.; Lokeshwar, T.; Mukesh, B.; Vishnu, B. Review on neem (Azadirachta indica): Thousand problems one solution. Int. Res. J. Pharm., 2011, 2, 97-102.
[4]
Rajakani, R.; Narnoliya, L.; Sangwan, N.S.; Sangwan, R.S.; Gupta, V. Subtractive transcriptomes of fruit and leaf reveal differential representation of transcripts in Azadirachta indica. Tree Genet. Genomes, 2014, 10, 1331-1351.
[http://dx.doi.org/10.1007/s11295-014-0764-7]
[5]
Nirmala, S.; Arun, S.; Bathula, N.; Sivanagamoorthi, M.; Ravichandiran, V. Antioxidant [In vitro] and analgesic activity [In vivo] of tannin fraction of stem bark of Ficus racemosa Linn. Res. J. Pharm. Biol. Chem. Sci., 2012, 3, 597-603.
[6]
Tiwari, R.; Verma, A.K.; Chakraborty, S.; Dhama, K.; Singh, S.V. Neem (Azadirachta indica) and its potential for safeguarding health of animals and humans: A Review. J. Biol. Sci., 2014, 14, 110.
[http://dx.doi.org/10.3923/jbs.2014.110.123]
[7]
Krishnan, N.M.; Pattnaik, S.; Deepak, S.A.; Hariharan, A.K.; Gaur, P.; Chaudhary, R.; Panda, B. De novo sequencing and assembly of Azadirachta indica fruit transcriptome. Curr. Sci., 2011, 1553-1561.
[8]
Krishnan, N.M.; Pattnaik, S.; Jain, P.; Gaur, P.; Choudhary, R.; Vaidyanathan, S.; Deepak, S.; Hariharan, A.K.; Krishna, P.B.; Nair, J.; Varghese, L.; Valivarthi, N.K.; Dhas, K.; Ramaswamy, K.; Panda, B. A draft of the genome and four transcriptomes of a medicinal and pesticidal angiosperm Azadirachta indica. BMC Genomics, 2012, 13, 464.
[http://dx.doi.org/10.1186/1471-2164-13-464] [PMID: 22958331]
[9]
Limasset, A.; Cazaux, B.; Rivals, E.; Peterlongo, P. Read mapping on de Bruijn graphs. BMC Bioinformatics, 2016, 17(1), 237.
[http://dx.doi.org/10.1186/s12859-016-1103-9] [PMID: 27306641]
[10]
Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70.
[http://dx.doi.org/10.1016/S0092-8674(00)81683-9] [PMID: 10647931]
[11]
Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell, 2011, 144(5), 646-674.
[http://dx.doi.org/10.1016/j.cell.2011.02.013] [PMID: 21376230]
[12]
Medjkane, S.; Weitzman, J.B. A reversible Warburg effect is induced by Theileria parasites to transform host leukocytes. Cell Cycle, 2013, 12(14), 2167-2168.
[http://dx.doi.org/10.4161/cc.25540] [PMID: 23803730]
[13]
Agrawal, S.; Bablani Popli, D.; Sircar, K.; Chowdhry, A. A review of the anticancer activity of Azadirachta indica (Neem) in oral cancer. J. Oral Biol. Craniofac. Res., 2020, 10(2), 206-209.
[http://dx.doi.org/10.1016/j.jobcr.2020.04.007] [PMID: 32489822]
[14]
Paul, R.; Prasad, M.; Sah, N.K. Anticancer biology of Azadirachta indica L (neem): A mini review. Cancer Biol. Ther., 2011, 12(6), 467-476.
[http://dx.doi.org/10.4161/cbt.12.6.16850] [PMID: 21743298]
[15]
Patel, S.M.; Nagulapalli Venkata, K.C.; Bhattacharyya, P.; Sethi, G.; Bishayee, A. Potential of neem (Azadirachta indica L.) for prevention and treatment of oncologic diseases. Semin. Cancer Biol., 2016, 40-41, 100-115.
[http://dx.doi.org/10.1016/j.semcancer.2016.03.002] [PMID: 27019417]
[16]
Hao, F.; Kumar, S.; Yadav, N.; Chandra, D. Neem components as potential agents for cancer prevention and treatment. Biochim. Biophys. Acta, 2014, 1846(1), 247-257.
[PMID: 25016141]
[17]
Gupta, S.C.; Prasad, S.; Tyagi, A.K.; Kunnumakkara, A.B.; Aggarwal, B.B. Neem (Azadirachta indica): An indian traditional panacea with modern molecular basis. Phytomedicine, 2017, 34, 14-20.
[http://dx.doi.org/10.1016/j.phymed.2017.07.001] [PMID: 28899496]
[18]
Singh, O.; Khanam, Z.; Ahmad, J. Neem (Azadirachta indica) in context of Intellectual Property Rights (IPR). Recent Res. Sci. Technol., 2011, 3, 80-84.
[19]
Toniolo, C.; Nicoletti, M.; Maggi, F.; Venditti, A. HPTLC determination of chemical composition variability in raw materials used in botanicals. Nat. Prod. Res., 2014, 28(2), 119-126.
[http://dx.doi.org/10.1080/14786419.2013.852546] [PMID: 24219430]
[20]
Gallo, F.R.; Multari, G.; Federici, E.; Palazzino, G.; Giambenedetti, M.; Petitto, V.; Poli, F.; Nicoletti, M. Chemical fingerprinting of Equisetum arvense L. using HPTLC densitometry and HPLC. Nat. Prod. Res., 2011, 25(13), 1261-1270.
[http://dx.doi.org/10.1080/14786419.2011.558015] [PMID: 21854173]
[21]
Akhila, A.; Rani, K. Chemistry of the neem tree (Azadirachta indica A. Juss.). Fortschr. Chem. Org. Naturst., 1999, 78, 47-149.
[http://dx.doi.org/10.1007/978-3-7091-6394-8_2] [PMID: 10592761]
[22]
Biswas, K.; Chattopadhyay, I.; Banerjee, R.K.; Bandyopadhyay, U. Biological activities and medicinal properties of neem (Azadirachta indica). Curr. Sci., 2002, 82, 1336-1345.
[23]
Qiu, Z.; Andrijauskaite, K.; Morris, J.; Wargovich, M.J. Disruption of epigenetic silencing in human colon cancer cells lines utilizing a novel supercritical co2 extract of neem leaf (Azadirachta indica). Anticancer Res., 2019, 39(10), 5473-5481.
[http://dx.doi.org/10.21873/anticanres.13740] [PMID: 31570441]
[24]
Joshi, J.; Sahu, O. Azadirachta indica leaves as antibacterial treatment on drinking water. Int. J. Clinic. Nut., 2014, 2, 36-40.
[25]
Sadasivam, P. Sree, g.; RamSugitha, B. Enhanced extraction and improved anticancer activity of neem (Azadirachta indica) leaves by electroporation technique. J. Inst. Electron. Telecommun. Eng., 2021, 1-11.
[26]
Djenontin, S. Tindo; Nadine, A.; Justine, Dangou; Wotto, V.D; Avlessi, F.; Ahoussi-Dahouenon, E.; Paul, L.; Pioch, D.; Codjo K.; Sohounhloue, D. Screening of repellent, termicidal and preventive activities on wood of Azadirachta indica and Carapa procera (Meliaceae) seeds oils. Int. Res. J. Biol. Sci., 2012, 1(3), 25-29.
[27]
Ujah, I.; Nsude, C.; Ani, O.; Alozieuwa, U.; Okwor, A. Phytochemicals of neem plant (Azadirachta indica) explains its use in traditional medicine and pest control. GSC Bio. Pharm. Sci., 2021, 14, 165-171.
[http://dx.doi.org/10.30574/gscbps.2021.14.2.0394]
[28]
Azman, M.A.; Sidek, H.J.; Halim, N.A.N.A.; Sahro, R.M.A.A.R.; Sharudin, M.S.M. Phytochemical screening and antibacterial activity of Azadirachta indica leaves extract on common skin infection bacteria; J. Intelek, 2016, p. 11.
[29]
Dash, S.; Dixit, S.; Sahoo, S. Phytochemical and biochemical characterizations from leaf extracts from azadirachta indica: An important medicinal plant. Biochem. Analyt. Biochem 2017. 06
[30]
Kumar, S.; Vandana, U. Agrawal, d.; HansJ, J.; Analgesic, J. Anti inflammatory and anti pyretic effects of Azadirachta indica (Neem) Leaf Extract in Albino Rats. Int. J. Sci. Res., 2015, 4, 713-721.
[31]
Ong, C.B.; Ng, L.Y.; Mohammad, A.W. A review of ZnO nanoparticles as solar photocatalysts: Synthesis, mechanisms and applications. Renew. Sustain. Energy Rev., 2018, 81, 536-551.
[http://dx.doi.org/10.1016/j.rser.2017.08.020]
[32]
Bhatti, M.; Tahira, A.; Chandio, A.; Almani, K.; Bhatti, A.; Waryani, B.; Nafady, A.; Ibupoto, Z. Enzymes and phytochemicals from neem extract robustly tuned the photocatalytic activity of ZnO for the degradation of malachite green (MG) in aqueous media. Res. Chem. Intermed., 2021, 47.
[http://dx.doi.org/10.1007/s11164-020-04391-6]
[33]
Patil, S.M.; Shirahatti, P.S. v B, C.K.; Ramu, R.; M N, N.P. Azadirachta indica A. Juss (neem) as a contraceptive: An evidence based review on its pharmacological efficiency. Phytomedicine, 2021, 88153596
[http://dx.doi.org/10.1016/j.phymed.2021.153596] [PMID: 34092456]
[34]
Alanis, A.J. Resistance to antibiotics: Are we in the post antibiotic era? Arch. Med. Res., 2005, 36(6), 697-705.
[http://dx.doi.org/10.1016/j.arcmed.2005.06.009] [PMID: 16216651]
[35]
Khanal, S. Qualitative and quantitative phytochemical screening of Azadirachta indica Juss. Plant parts. Int. J. Appl. Sci. Biotechnol., 2021, 9, 122-127.
[http://dx.doi.org/10.3126/ijasbt.v9i2.38050]
[36]
Nahak, D.G.; Sahu, R. Antioxidant activity and phytochemical evaluation of Plumbago zeylanicalinn. In vivo and in vitro. Continental J. Pharm. Sci., 2010, 4, 28-34.
[37]
Karimi, A.; Moradi, M.T.; Gafourian, A. In vitro anti adenovirus activity and antioxidant potential of Pistacia atlantica Desf. leaves. Res. J. Pharmacog; RJP, 2020, p. 7.
[38]
Hassan, W.; Rehman, S.; Noreen, H.; Zafar, M. Piper nigrum protects against fe (II) mediated lipid peroxidation in phopholipids liposomes: Analytical and Biochemical Analysis. Letters Appl. NanoBioSci., 2021, 10, 2729-2741.
[http://dx.doi.org/10.33263/LIANBS104.27292741]
[39]
Ouerfelli, M.; Villasante, J.; Ben Kaâb, L.B.; Almajano, M. Effect of neem (Azadirachta indica L.) on lipid oxidation in raw chilled beef patties. Antioxidants, 2019, 8(8), 305.
[http://dx.doi.org/10.3390/antiox8080305] [PMID: 31416174]
[40]
Mosaddek, A.S.M.; Rashid, M.M.U. A comparative study of the anti inflammatory effect of aqueous extract of neem leaf and dexamethasone. Bangladesh J. Pharmacol., 2008, 3, 44-47.
[http://dx.doi.org/10.3329/bjp.v3i1.836]
[41]
Schumacher, M.; Cerella, C.; Reuter, S.; Dicato, M.; Diederich, M. Anti-inflammatory, pro-apoptotic, and anti proliferative effects of a methanolic neem (Azadirachta indica) leaf extract are mediated via modulation of the nuclear factor-κB pathway. Genes Nutr., 2011, 6(2), 149-160.
[http://dx.doi.org/10.1007/s12263-010-0194-6] [PMID: 21484152]
[42]
Bhattacharya, A.; Tiwari, P.; Sahu, P.K.; Kumar, S. A review of the phytochemical and pharmacological characteristics of Moringa oleifera. J. Pharm. Bioallied Sci., 2018, 10(4), 181-191.
[http://dx.doi.org/10.4103/JPBS.JPBS_126_18] [PMID: 30568375]
[43]
Imam, H.; Azad, H.; Makbul, S. Neem (Azadirachta indica A. Juss)-A nature’s drugstore: An overview. Int. Res. J. Biol. Sci., 2012, 1, 76.
[44]
Okpe, A.; Shu, E.; Nwadike, K. J, U.; Nubila, N.; Aniagor, E. Effects of Fractionated Neem Leaf Extract (IRC) on Blood Glucose Level in Alloxan Induced Diabetic Wistar Rats. Int. J. Diabetes Clin. Res., 2019, 6.
[45]
Morgan, E.D. Azadirachtin, a scientific gold mine. Bioorg. Med. Chem., 2009, 17(12), 4096-4105.
[http://dx.doi.org/10.1016/j.bmc.2008.11.081] [PMID: 19112026]
[46]
Kashif, M.; Hwang, Y.; Hong, G.; Kim, G. In vitro comparative cytotoxic effect of Nimbolide: A limonoid from Azadirachta indica (Neem tree) on cancer cell lines and normal cell lines through MTT assay. Pak. J. Pharm. Sci., 2017, 30(3), 967-973.
[PMID: 28655693]
[47]
Kikuchi, T.; Ishii, K.; Noto, T.; Takahashi, A.; Tabata, K.; Suzuki, T.; Akihisa, T. Cytotoxic and apoptosis inducing activities of limonoids from the seeds of Azadirachta indica (neem). J. Nat. Prod., 2011, 74(4), 866-870.
[http://dx.doi.org/10.1021/np100783k] [PMID: 21381696]
[48]
Murakami, A.; Ashida, H.; Terao, J. Multitargeted cancer prevention by quercetin. J. Cancer Lett, 2008, 269(2), 315-325.
[http://dx.doi.org/10.1016/j.canlet.2008.03.046] [PMID: 18467024]
[49]
Kamath, S.G.; Chen, N.; Xiong, Y.; Wenham, R.; Apte, S.; Humphrey, M.; Cragun, J.; Lancaster, J.M. Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation. Int. J. Gynecol. Cancer, 2009, 19(9), 1564-1569.
[http://dx.doi.org/10.1111/IGC.0b013e3181a83135] [PMID: 19955938]
[50]
Dal Piaz, F.; Terracciano, S.; De Tommasi, N.; Braca, A. Hsp90 activity modulation by plant secondary metabolites. Planta Med., 2015, 81(14), 1223-1239.
[http://dx.doi.org/10.1055/s-0035-1546251] [PMID: 26227505]
[51]
Dutta Gupta, S.; Bommaka, M.K.; Banerjee, A. Inhibiting protein protein interactions of Hsp90 as a novel approach for targeting cancer. Eur. J. Med. Chem., 2019, 178, 48-63.
[http://dx.doi.org/10.1016/j.ejmech.2019.05.073] [PMID: 31176095]
[52]
Moga, M.A. Bălan, A.; Anastasiu, C.V.; Dimienescu, O.G.; Neculoiu, C.D.; Gavriș C. An overview on the anticancer activity of Azadirachta indica (Neem) in gynecological cancers. Int. J. Mol. Sci., 2018, 19(12), 3898.
[http://dx.doi.org/10.3390/ijms19123898] [PMID: 30563141]
[53]
Brandt, G.E.; Schmidt, M.D.; Prisinzano, T.E.; Blagg, B.S. Gedunin, a novel hsp90 inhibitor: Semisynthesis of derivatives and preliminary structure-activity relationships. J. Med. Chem., 2008, 51(20), 6495-6502.
[http://dx.doi.org/10.1021/jm8007486] [PMID: 18816111]
[54]
Cazal, C.M.; Choosang, K.; Severino, V.G.; Soares, M.S.; Sarria, A.L.; Fernandes, J.B.; Silva, M.F.; Vieira, P.C.; Pakkong, P.; Almeida, G.M.; Vasconcelos, M.H.; Nascimento, M.S.; Pinto, M.M. Evaluation of effect of triterpenes and limonoids on cell growth, cell cycle and apoptosis in human tumor cell line. Anticancer. Agents Med. Chem., 2010, 10(10), 769-776.
[http://dx.doi.org/10.2174/187152010794728620] [PMID: 21269253]
[55]
Akihisa, T.; Seino, K.; Kaneko, E.; Watanabe, K.; Tochizawa, S.; Fukatsu, M.; Banno, N.; Metori, K.; Kimura, Y. Melanogenesis inhibitory activities of iridoid-, hemiterpene-, and fatty acid glycosides from the fruits of Morinda citrifolia (Noni). J. Oleo Sci., 2010, 59(1), 49-57.
[http://dx.doi.org/10.5650/jos.59.49] [PMID: 20032599]
[56]
Patwardhan, C.A.; Fauq, A.; Peterson, L.B.; Miller, C.; Blagg, B.S.; Chadli, A. Gedunin inactivates the co chaperone p23 protein causing cancer cell death by apoptosis. J. Biol. Chem., 2013, 288(10), 7313-7325.
[http://dx.doi.org/10.1074/jbc.M112.427328] [PMID: 23355466]
[57]
Hieronymus, H.; Lamb, J.; Ross, K.N.; Peng, X.P.; Clement, C.; Rodina, A.; Nieto, M.; Du, J.; Stegmaier, K.; Raj, S.M.; Maloney, K.N.; Clardy, J.; Hahn, W.C.; Chiosis, G.; Golub, T.R. Gene expression signature based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell, 2006, 10(4), 321-330.
[http://dx.doi.org/10.1016/j.ccr.2006.09.005] [PMID: 17010675]
[58]
Boopalan, T.; Chaudhary, A.; Murali, S.; Arumugam, A.; Lopez, R.; Nandy, S.; Gutierrez, C.; Parada, J.; Agullo, P.; Lakshmanaswamy, R. Abstract 2264: Anticancer effect of gedunin against pancreatic cancer cell lines. Cancer Res., 2013, 73, 2264-2264.
[59]
Nwokwu, C.; Samarakoon, S.; Karunaratne, N.; Katuwavila, N.; Pamunuwa, G.; Ediriweera, M.; Tennekoon, K. Induction of apoptosis in response to improved gedunin by liposomal nano encapsulation in human non small cell lung cancer (NCI-H292) cell line. Trop. J. Pharm. Res., 2017, 16, 2079-2087.
[http://dx.doi.org/10.4314/tjpr.v16i9.6]
[60]
Jiao, J.; Kang, F.; Zhang, J.; Quan, Z.; Wen, W.; Zhao, X.; Ma, S.; Wu, P.; Yang, F.; Guo, W.; Yang, X.; Yuan, J.; Shi, Y.; Wang, J.; Qin, W. Establishment and prospective validation of an SUV cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by Ga-PSMA PET/CT: A real-world study. Theranostics, 2021, 11(17), 8396-8411.
[http://dx.doi.org/10.7150/thno.58140] [PMID: 34373749]
[61]
Bang, A.; Schoenfeld, J.D. Immunotherapy and radiotherapy for metastatic cancers. Ann. Palliat. Med., 2019, 8(3), 312-325.
[http://dx.doi.org/10.21037/apm.2018.07.10] [PMID: 30180743]
[62]
Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414(6859), 105-111.
[http://dx.doi.org/10.1038/35102167] [PMID: 11689955]
[63]
Mayan, K.; Samarakoon, S.; Tennekoon, K.; Siriwardhana, A.; Valverde, J. Evaluation of selected natural compounds for cancer stem cells targeted anti cancer activity: A molecular docking study. European J. Med. Plants, 2016, 15, 1-21.
[http://dx.doi.org/10.9734/EJMP/2016/27847]
[64]
Tharmarajah, L.; Samarakoon, S.R.; Ediriweera, M.K.; Piyathilaka, P.; Tennekoon, K.H.; Senathilake, K.S.; Rajagopalan, U.; Galhena, P.B.; Thabrew, I. In vitro anticancer effect of gedunin on human teratocarcinomal (NTERA-2) cancer stem like cells. BioMed Res. Int., 2017, 2017, 2413197-2413197.
[http://dx.doi.org/10.1155/2017/2413197] [PMID: 28680880]
[65]
Conley, C.C.; Ketcher, D.; Reblin, M.; Kasting, M.L.; Cragun, D.; Kim, J.; Ashing, K.T.; Knott, C.L.; Hughes-Halbert, C.; Pal, T.; Vadaparampil, S.T. The big reveal: Family disclosure patterns of BRCA genetic test results among young Black women with invasive breast cancer. J. Genet. Couns., 2020, 29(3), 410-422.
[http://dx.doi.org/10.1002/jgc4.1196] [PMID: 31912597]
[66]
Ataollahi, M.R.; Sharifi, J.; Paknahad, M.R.; Paknahad, A. Breast cancer and associated factors: A review. J. Med. Life, 2015, 8(4), 6-11.
[PMID: 28316699]
[67]
Safaee, A.; Moghimi, D.B.; Zeighami, B.; Tabatabaee, H.; Pourhoseingholi, M. Predictors of quality of life in breast cancer patients under chemotherapy. Indian J. Cancer, 2008, 45(3), 107-111.
[http://dx.doi.org/10.4103/0019-509X.44066] [PMID: 19018114]
[68]
Sadighi, S.; Zokaasadi, M.; Kasaeian, A.; Maghsudi, S.; Jahanzad, I. KamranzadehFumani, H. Predictors of adherence to a new erythropoiesis-stimulating agent inpatient ordering policy: A cross sectional study. PLoS One, 2017, 12e0182444
[http://dx.doi.org/10.1371/journal.pone.0182444] [PMID: 28771563]
[69]
Lynch, H.T.; Watson, P.; Conway, T.A.; Lynch, J.F. Clinical/genetic features in hereditary breast cancer. Breast Cancer Res. Treat., 1990, 15(2), 63-71.
[http://dx.doi.org/10.1007/BF01810778] [PMID: 2322650]
[70]
Fitzmaurice, C.; Dicker, D.; Pain, A.; Hamavid, H.; Moradi-Lakeh, M.; MacIntyre, M.F.; Allen, C.; Hansen, G.; Woodbrook, R.; Wolfe, C.; Hamadeh, R.R.; Moore, A.; Werdecker, A.; Gessner, B.D.; Te Ao, B.; McMahon, B.; Karimkhani, C.; Yu, C.; Cooke, G.S.; Schwebel, D.C.; Carpenter, D.O.; Pereira, D.M.; Nash, D.; Kazi, D.S.; De Leo, D.; Plass, D.; Ukwaja, K.N.; Thurston, G.D.; Jin, Y. K.; Simard, E.P.; Mills, E.; Park, E.K.; Catalá-López, F.; deVeber, G.; Gotay, C.; Khan, G.; Hosgood, H.D., III; Santos, I.S.; Leasher, J.L.; Singh, J.; Leigh, J.; Jonas, J.B.; Sanabria, J.; Beardsley, J.; Jacobsen, K.H.; Takahashi, K.; Franklin, R.C.; Ronfani, L.; Montico, M.; Naldi, L.; Tonelli, M.; Geleijnse, J.; Petzold, M.; Shrime, M.G.; Younis, M.; Yonemoto, N.; Breitborde, N.; Yip, P.; Pourmalek, F.; Lotufo, P.A.; Esteghamati, A.; Hankey, G.J.; Ali, R.; Lunevicius, R.; Malekzadeh, R.; Dellavalle, R.; Weintraub, R.; Lucas, R.; Hay, R.; Rojas, D.; Westerman, R.; Sepanlou, S.G.; Nolte, S.; Patten, S.; Weichenthal, S.; Abera, S.F.; Fereshtehnejad, S.M.; Shiue, I.; Driscoll, T.; Vasankari, T.; Alsharif, U.; Rahimi-Movaghar, V.; Vlassov, V.V.; Marcenes, W.S.; Mekonnen, W.; Melaku, Y.A.; Yano, Y.; Artaman, A.; Campos, I.; MacLachlan, J.; Mueller, U.; Kim, D.; Trillini, M.; Eshrati, B.; Williams, H.C.; Shibuya, K.; Dandona, R.; Murthy, K.; Cowie, B.; Amare, A.T.; Antonio, C.A.; Castañeda-Orjuela, C.; van Gool, C.H.; Violante, F.; Oh, I.H.; Deribe, K.; Soreide, K.; Knibbs, L.; Kereselidze, M.; Green, M.; Cardenas, R.; Roy, N.; Tillmann, T.; Li, Y.; Krueger, H.; Monasta, L.; Dey, S.; Sheikhbahaei, S.; Hafezi, N.N.; Kumar, G.A.; Sreeramareddy, C.T.; Dandona, L.; Wang, H.; Vollset, S.E.; Mokdad, A.; Salomon, J.A.; Lozano, R.; Vos, T.; Forouzanfar, M.; Lopez, A.; Murray, C.; Naghavi, M. The Global burden of cancer 2013. JAMA Oncol., 2015, 1(4), 505-527.
[http://dx.doi.org/10.1001/jamaoncol.2015.0735] [PMID: 26181261]
[71]
Allemani, C.; Weir, H.K.; Carreira, H.; Harewood, R.; Spika, D.; Wang, X.S.; Bannon, F.; Ahn, J.V.; Johnson, C.J.; Bonaventure, A.; Marcos, G.R.; Stiller, C.; Azevedo e Silva, G.; Chen, W.Q.; Ogunbiyi, O.J.; Rachet, B.; Soeberg, M.J.; You, H.; Matsuda, T.; Bielska, L.M.; Storm, H.; Tucker, T.C.; Coleman, M.P. Global surveillance of cancer survival 1995–2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet, 2015, 385, 977-1010.
[http://dx.doi.org/10.1016/S0140-6736(14)62038-9] [PMID: 25467588]
[72]
Lin, N.U.; Claus, E.; Sohl, J.; Razzak, A.R.; Arnaout, A.; Winer, E.P. Sites of distant recurrence and clinical outcomes in patients with metastatic triple negative breast cancer: High incidence of central nervous system metastases. Cancer, 2008, 113(10), 2638-2645.
[http://dx.doi.org/10.1002/cncr.23930] [PMID: 18833576]
[73]
Bianchini, G.; Balko, J.M.; Mayer, I.A.; Sanders, M.E.; Gianni, L. Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol., 2016, 13(11), 674-690.
[http://dx.doi.org/10.1038/nrclinonc.2016.66] [PMID: 27184417]
[74]
Lehmann, B.D.; Bauer, J.A.; Chen, X.; Sanders, M.E.; Chakravarthy, A.B.; Shyr, Y.; Pietenpol, J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest., 2011, 121(7), 2750-2767.
[http://dx.doi.org/10.1172/JCI45014] [PMID: 21633166]
[75]
Masuda, H.; Baggerly, K.A.; Wang, Y.; Zhang, Y.; Gonzalez-Angulo, A.M.; Meric-Bernstam, F.; Valero, V.; Lehmann, B.D.; Pietenpol, J.A.; Hortobagyi, G.N.; Symmans, W.F.; Ueno, N.T. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin. Cancer Res., 2013, 19(19), 5533-5540.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-0799] [PMID: 23948975]
[76]
De Summa, S.; Pinto, R.; Sambiasi, D.; Petriella, D.; Paradiso, V.; Paradiso, A.; Tommasi, S. BRCAness: A deeper insight into basal like breast tumors. Ann Oncol, , 2013, 24(8) viii13-viii21.
[http://dx.doi.org/10.1093/annonc/mdt306]
[77]
Turner, N.; Tutt, A.; Ashworth, A. Hallmarks of ‘BRCANESS’ in sporadic cancers. Nat. Rev. Cancer, 2004, 4(10), 814-819.
[http://dx.doi.org/10.1038/nrc1457] [PMID: 15510162]
[78]
Esteller, M.; Silva, J.M.; Dominguez, G.; Bonilla, F.; Matias, G.X.; Lerma, E.; Bussaglia, E.; Prat, J.; Harkes, I.C.; Repasky, E.A.; Gabrielson, E.; Schutte, M.; Baylin, S.B.; Herman, J.G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst., 2000, 92(7), 564-569.
[http://dx.doi.org/10.1093/jnci/92.7.564] [PMID: 10749912]
[79]
Weigman, V.J.; Chao, H.H.; Shabalin, A.A.; He, X.; Parker, J.S.; Nordgard, S.H.; Grushko, T.; Huo, D.; Nwachukwu, C.; Nobel, A.; Kristensen, V.N.; Børresen, A.L.; Olopade, O.I.; Perou, C.M. Basal like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res. Treat., 2012, 133(3), 865-880.
[http://dx.doi.org/10.1007/s10549-011-1846-y] [PMID: 22048815]
[80]
Byrski, T.; Gronwald, J.; Huzarski, T.; Grzybowska, E.; Budryk, M.; Stawicka, M.; Mierzwa, T.; Szwiec, M.; Wisniowski, R.; Siolek, M.; Dent, R.; Lubinski, J.; Narod, S. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J. Clin. Oncol., 2010, 28(3), 375-379.
[http://dx.doi.org/10.1200/JCO.2008.20.7019] [PMID: 20008645]
[81]
von Minckwitz, G.; Schneeweiss, A.; Loibl, S.; Salat, C.; Denkert, C.; Rezai, M.; Blohmer, J.U.; Jackisch, C.; Paepke, S.; Gerber, B.; Zahm, D.M.; Kümmel, S.; Eidtmann, H.; Klare, P.; Huober, J.; Costa, S.; Tesch, H.; Hanusch, C.; Hilfrich, J.; Khandan, F.; Fasching, P.A.; Sinn, B.V.; Engels, K.; Mehta, K.; Nekljudova, V.; Untch, M. Neoadjuvant carboplatin in patients with triple negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol., 2014, 15(7), 747-756.
[http://dx.doi.org/10.1016/S1470-2045(14)70160-3] [PMID: 24794243]
[82]
Tutt, A.; Tovey, H.; Cheang, M.C.U.; Kernaghan, S.; Kilburn, L.; Gazinska, P.; Owen, J.; Abraham, J.; Barrett, S.; Barrett, L.P.; Brown, R.; Chan, S.; Dowsett, M.; Flanagan, J.M.; Fox, L.; Grigoriadis, A.; Gutin, A.; Harper, W.C.; Hatton, M.Q.; Hoadley, K.A.; Parikh, J.; Parker, P.; Perou, C.M.; Roylance, R.; Shah, V.; Shaw, A.; Smith, I.E.; Timms, K.M.; Wardley, A.M.; Wilson, G.; Gillett, C.; Lanchbury, J.S.; Ashworth, A.; Rahman, N.; Harries, M.; Ellis, P.; Pinder, S.E.; Bliss, J.M. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial. Nat. Med., 2018, 24(5), 628-637.
[http://dx.doi.org/10.1038/s41591-018-0009-7] [PMID: 29713086]
[83]
Xu, J.; Keenan, T.E.; Overmoyer, B.; Tung, N.M.; Gelman, R.S.; Habin, K.; Garber, J.E.; Ellisen, L.W.; Winer, E.P.; Goss, P.E.; Yeap, B.Y.; Chabner, B.A.; Isakoff, S.J. Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. Breast Cancer Res. Treat., 2021, 189(3), 641-651.
[http://dx.doi.org/10.1007/s10549-021-06292-7] [PMID: 34417675]
[84]
Gucalp, A.; Tolaney, S.; Isakoff, S.J.; Ingle, J.N.; Liu, M.C.; Carey, L.A.; Blackwell, K.; Rugo, H.; Nabell, L.; Forero, A.; Stearns, V.; Doane, A.S.; Danso, M.; Moynahan, M.E.; Momen, L.F.; Gonzalez, J.M.; Akhtar, A.; Giri, D.D.; Patil, S.; Feigin, K.N.; Hudis, C.A.; Traina, T.A.; Phase, I.I. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor negative metastatic Breast Cancer. Clin. Cancer Res., 2013, 19(19), 5505-5512.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-3327] [PMID: 23965901]
[85]
Caldas, L.E.; Cerchietti, L.; Ahn, J.H.; Clement, C.C.; Robles, A.I.; Rodina, A.; Moulick, K.; Taldone, T.; Gozman, A.; Guo, Y.; Wu, N.; de Stanchina, E.; White, J.; Gross, S.S.; Ma, Y.; Varticovski, L.; Melnick, A.; Chiosis, G. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl. Acad. Sci. USA, 2009, 106(20), 8368-8373.
[http://dx.doi.org/10.1073/pnas.0903392106] [PMID: 19416831]
[86]
Hon, J.D.; Singh, B.; Sahin, A.; Du, G.; Wang, J.; Wang, V.Y.; Deng, F.M.; Zhang, D.Y.; Monaco, M.E.; Lee, P. Breast cancer molecular subtypes: From TNBC to QNBC. Am. J. Cancer Res., 2016, 6(9), 1864-1872.
[PMID: 27725895]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy